Cargando…
C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
BACKGROUND: Cachexia is defined as an involuntary loss of weight, characterized by a loss of skeletal muscle mass with or without fat mass loss. It increases mortality risk and decreases quality of life in patients with lymphoma or myeloma. Early markers of cachexia are not identified. The objective...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153683/ https://www.ncbi.nlm.nih.gov/pubmed/32300444 http://dx.doi.org/10.14740/jh536 |
_version_ | 1783521695560105984 |
---|---|
author | Mallard, Joris Gagez, Anne-Laure Baudinet, Cedric Herbinet, Aline Maury, Jonathan Bernard, Pierre Louis Cartron, Guillaume |
author_facet | Mallard, Joris Gagez, Anne-Laure Baudinet, Cedric Herbinet, Aline Maury, Jonathan Bernard, Pierre Louis Cartron, Guillaume |
author_sort | Mallard, Joris |
collection | PubMed |
description | BACKGROUND: Cachexia is defined as an involuntary loss of weight, characterized by a loss of skeletal muscle mass with or without fat mass loss. It increases mortality risk and decreases quality of life in patients with lymphoma or myeloma. Early markers of cachexia are not identified. The objective of this work was to identify risk factor of cachexia in a cohort of patients with hematological malignancies to develop strategies to prevent cachexia and its consequences. METHODS: Clinical and biological parameters were collected before and at the end of the treatment. Quantification of weight loss during cachexia was performed by the method of Martin. Clinical responses to treatment of patients with lymphoma or myeloma were monitored. RESULTS: Thirty-eight percent of the 145 patients enrolled were cachectic at the end of treatment. Classical prognostic disease scores at the time of diagnosis seemed to be not associated with cachexia observed at the end of treatment. Only C-reactive protein (CRP) > 54 mg/L seemed to be a risk factor of cachexia (P = 0.023, odds ratio (OR): 5.94 (1.55 - 39.14), confidence interval (CI): 1.55 - 39.14). Those results were confirmed by bootstrap analysis. CONCLUSION: This study highlights that high CRP level at diagnosis seems to be a risk factor for cachexia during treatment, permitting to identify patients at risk and in future to implement preventive strategies. |
format | Online Article Text |
id | pubmed-7153683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-71536832020-04-16 C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients Mallard, Joris Gagez, Anne-Laure Baudinet, Cedric Herbinet, Aline Maury, Jonathan Bernard, Pierre Louis Cartron, Guillaume J Hematol Short Communication BACKGROUND: Cachexia is defined as an involuntary loss of weight, characterized by a loss of skeletal muscle mass with or without fat mass loss. It increases mortality risk and decreases quality of life in patients with lymphoma or myeloma. Early markers of cachexia are not identified. The objective of this work was to identify risk factor of cachexia in a cohort of patients with hematological malignancies to develop strategies to prevent cachexia and its consequences. METHODS: Clinical and biological parameters were collected before and at the end of the treatment. Quantification of weight loss during cachexia was performed by the method of Martin. Clinical responses to treatment of patients with lymphoma or myeloma were monitored. RESULTS: Thirty-eight percent of the 145 patients enrolled were cachectic at the end of treatment. Classical prognostic disease scores at the time of diagnosis seemed to be not associated with cachexia observed at the end of treatment. Only C-reactive protein (CRP) > 54 mg/L seemed to be a risk factor of cachexia (P = 0.023, odds ratio (OR): 5.94 (1.55 - 39.14), confidence interval (CI): 1.55 - 39.14). Those results were confirmed by bootstrap analysis. CONCLUSION: This study highlights that high CRP level at diagnosis seems to be a risk factor for cachexia during treatment, permitting to identify patients at risk and in future to implement preventive strategies. Elmer Press 2019-06 2019-06-30 /pmc/articles/PMC7153683/ /pubmed/32300444 http://dx.doi.org/10.14740/jh536 Text en Copyright 2019, Mallard et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Mallard, Joris Gagez, Anne-Laure Baudinet, Cedric Herbinet, Aline Maury, Jonathan Bernard, Pierre Louis Cartron, Guillaume C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients |
title | C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients |
title_full | C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients |
title_fullStr | C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients |
title_full_unstemmed | C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients |
title_short | C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients |
title_sort | c-reactive protein level: a key predictive marker of cachexia in lymphoma and myeloma patients |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153683/ https://www.ncbi.nlm.nih.gov/pubmed/32300444 http://dx.doi.org/10.14740/jh536 |
work_keys_str_mv | AT mallardjoris creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients AT gagezannelaure creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients AT baudinetcedric creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients AT herbinetaline creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients AT mauryjonathan creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients AT bernardpierrelouis creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients AT cartronguillaume creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients |